口服孕激素预防复发性早产:系统评价与Meta分析
该系统评价与Meta分析纳入3项随机对照试验共386例(口服孕激素196例、安慰剂190例)有自发性早产史的无症状单胎孕妇,比较口服孕激素与安慰剂。口服孕激素组早产<37周风险显著降低(42% vs 63%,RR 0.68,95%CI 0.55-0.84),围产儿死亡、新生儿重症监护入住、呼吸窘迫综合征均显著减少,但头晕、嗜睡、阴道干燥等母体不良反应增加,无严重不良反应。
要点
- 口服孕激素较安慰剂显著降低<37周早产风险(42% vs 63%,RR 0.68,95%CI 0.55-0.84)。
- 口服孕激素组围产儿死亡5% vs 安慰剂17%(RR 0.32,95%CI 0.16-0.63)。
- 口服孕激素增加头晕、嗜睡、阴道干燥等母体不良反应,但无严重不良反应。
核心结论
- 口服孕激素似可有效预防有既往自发性早产史的无症状单胎妊娠的复发性早产,并降低围产儿发病率和死亡率。
- 与安慰剂相比,口服孕激素治疗的不良反应增加,但均不严重。
- 作者认为需要进一步开展口服孕激素与其他已确立的复发性早产预防疗法的随机研究。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Scopus、ClinicalTrials.gov、PROSPERO、EMBASE和Cochrane Register,从各数据库建库至2018年4月。
- 纳入有既往自发性单胎早产史的无症状单胎妊娠随机对照试验,比较口服孕激素与安慰剂、无治疗或其他早产干预。
- 排除准随机试验、随机分组时存在早产临产/胎膜早破者及多胎妊娠。
- 共检索到79项不同研究,最终纳入3项口服孕激素与安慰剂对照试验,共386例患者(口服孕激素196例、安慰剂190例);无符合纳入标准的口服孕激素与其他干预对照研究。
- 所有分析采用意向性治疗原则,效应量以相对危险度或均数差报告,I²>30%用于识别异质性。
主要发现
- 口服孕激素组<37周早产发生率42% vs 安慰剂组63%(P=.0005;RR 0.68;95%CI 0.55-0.84)。
- <34周早产发生率口服孕激素组29% vs 安慰剂组53%(P<.00001;RR 0.55;95%CI 0.43-0.71)。
- 分娩孕周口服孕激素组较安慰剂组增加(均数差1.71周;95%CI 1.11-2.30)。
- 围产儿死亡口服孕激素组5% vs 安慰剂组17%(P=.001;RR 0.32;95%CI 0.16-0.63)。
- 新生儿重症监护入住RR 0.39(95%CI 0.25-0.61)、呼吸窘迫综合征RR 0.21(95%CI 0.05-0.93)、出生体重均数差435.06 g(95%CI 324.59-545.52),均支持口服孕激素组。
临床怎么用
- 作者认为口服孕激素似可有效预防有既往自发性早产史的无症状单胎妊娠的复发性早产,并降低围产儿发病率和死亡率。
- 作者指出口服孕激素治疗的不良反应增加但均不严重。
- 作者认为需要进一步开展口服孕激素与其他已确立的复发性早产预防疗法的随机研究。
局限性
- 作者认为需要进一步开展口服孕激素与其他已确立的复发性早产预防疗法的随机研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE DATA: The purpose of this study was to perform a systematic review and metaanalysis of randomized controlled trials on oral progesterone compared with placebo or other interventions for preterm birth prevention in singleton pregnancies with previous spontaneous preterm birth. The primary outcome was preterm birth at <37 weeks gestation; the secondary outcomes included preterm birth rate at <34 weeks gestation, neonatal morbidity/death, and maternal side-effects. STUDY: Searches were performed in PubMed, Scopus, ClinicalTrials.gov, PROSPERO, EMBASE, and the Cochrane Register with the use of a combination of words related to "preterm birth," "preterm delivery," "progesterone," "progestogens," and "oral" from inception of each database to April 2018. Additionally, systematic reviews on progesterone for preterm birth prevention that were identified in our search were also reviewed for additional studies. We included all randomized trials of asymptomatic singleton gestations with previous spontaneous singleton preterm birth that had been randomized to prophylactic treatment with oral progesterone vs placebo, no treatment, or other preterm birth intervention. Exclusion criteria included quasirandomized trials, trials that involved women with preterm labor/membrane rupture at the time of randomization or multiple gestations. STUDY APPRAISAL AND SYNTHESIS METHODS: The risk of bias and quality of evidence were assessed for each study. All analyses were done with an intention-to-treat approach. The primary outcome was incidence of preterm birth at <37 weeks gestation; the secondary outcomes included preterm birth at <34 and <28 weeks gestation, maternal adverse events, maternal serum progesterone level, and neonatal morbidity and death. Summary measures were reported as relative risk or mean difference. I2 >30% was used to identify heterogeneity. RESULTS: The search strategy identified 79 distinct studies. Three trials on oral progesterone vs placebo (involved 386 patients: 196 in oral progesterone and 190 in placebo) met the inclusion criteria; there were no studies on oral progesterone vs other intervention that met inclusion criteria. Metaanalysis demonstrated a significantly decreased risk of preterm birth at <37 weeks gestation (42% vs 63%; P=.0005; relative risk, 0.68; 95% confidence interval, 0.55-0.84), preterm birth at <34 weeks gestation (29% vs 53%; P<.00001; relative risk, 0.55; 95% confidence interval, 0.43-0.71), and increased gestational age of delivery (mean difference, 1.71 weeks; 95% confidence interval, 1.11-2.30) with oral progesterone compared with placebo. There was a significantly lower rate of perinatal death (5% vs 17%; P=.001; relative risk 0.32; 95% confidence interval, 0.16-0.63), neonatal intensive care admission (relative risk, 0.39; 95% confidence interval, 0.25-0.61), respiratory distress syndrome (relative risk, 0.21; 95% confidence interval, 0.05-0.93), and higher birthweight (mean difference, 435.06 g; 95% confidence interval, 324.59-545.52) with oral progesterone. There was a higher rate of maternal adverse effects with oral progesterone that included dizziness (relative risk, 2.95; 95% confidence interval, 1.47-5.90), somnolence (relative risk, 2.06; 95% confidence interval, 1.29-3.30), and vaginal dryness (relative risk, 2.37; 95% confidence interval, 1.10-5.11); no serious adverse effects were noted. CONCLUSION: Oral progesterone appears to be effective for the prevention of recurrent preterm birth and a reduction in perinatal morbidity and mortality rates in asymptomatic singleton gestations with a history of previous spontaneous preterm birth compared with placebo. There were also increased adverse effects with oral progesterone therapy compared with placebo, although none were serious. Further randomized study on oral progesterone compared with other established therapies for the prevention of recurrent preterm birth are warranted.
引用
- Boelig RC, Della Corte L, Ashoush S, et al. Oral progesterone for the prevention of recurrent preterm birth: systematic review and metaanalysis. Am J Obstet Gynecol MFM. 2019. PMID: 31172132. doi:10.1016/j.ajogmf.2019.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。